South Korean launch for Teijin's novel gout drug febuxostat
This article was originally published in Scrip
Executive Summary
Teijin Pharma's novel gout drug febuxostat has been launched in South Korea through the local licensee SK Chemicals, as Feburic, for the treatment of chronic hyperuricaemia in patients with the disorder.